Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2021.12.01

Sai Life Sciences’ pharmaceutical API manufacturing site receives Certificate of Inspection from PMDA, Japan

Sai Life Sciences’ pharmaceutical API manufacturing site receives Certificate of Inspection from PMDA, Japan

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), today announced that the Japanese regulatory agency, Pharmaceuticals and Medical Devices Agency (PMDA) completed a paper-based compliance inspection of its intermediate & API manufacturing facility in Bidar, India and issued a Certificate of Inspection. Previously, the agency had conducted a three-day long physical audit in the year 2016 and had issued a Certificate of Inspection.

Making the announcement, Krishna Kanumuri, CEO & Managing Director said, “We are delighted to receive a formal Certificate of Inspection from PMDA, Japan. We have been a reliable supplier of pharmaceutical API to the Japanese market for over five years and this certification is a reaffirmation of our commitment to fulfill the most stringent quality standards of the regulatory agency.”

Sai Life Sciences has a growing presence in the Japanese market. It was the launch site for commercial API supplies of an NCE to Japan and has supplied over 50 tonnes of API over the past five years. It is a supplier of registered starting materials for three commercial APIs. The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product. From a drug discovery perspective, the company has helped several biotech and pharma companies advance programs from HIT to lead optimization / candidate stage, through its chemistry, biology and DMPK services. The company opened its representative office in Tokyo, Japan last year, which serves as base for the company’s outreach to innovator pharmaceutical and biotech companies in Japan and other countries in the Asia Pacific region.

Some of the notable highlights of the Bidar manufacturing facility of Sai Life Sciences:

. 100% track record of successful inspections –
-USFDA (4 times)
- PMDA (twice)
- COFEPRIS, Mexico (once)
. 450KL capacity with 50 production trains
. Containment level of 1µg/m3
. 0.25 – 10 KL reactor sizes
. 21CFR compliant single fluid automation system
. 11 clean rooms of ISO – 8 (Class 100,000)
. Lyophilization at pilot & commercial scale
. Chromatography at commercial scale
. Cryo reactions at 2.5 KL, 4 KL & 5 KL scale
. Highly Potent API facility (Q1-2022)
. Amidites facility (Q1-2022)
. Upcoming facilities
- Dedicated facility for companion animal health products
- Additional 200KL intermediate and API manufacturing capacity
. ISO 14001:2015 and ISO 45001:2018 certified
. Zero liquid discharge facility
. Multiple awards for excellence in energy management and EHS practices.

Share article

More News

2025.09.05

Reviving Kudikunta Lake: Bringing nature and community closer together

As part of its Corporate Social Responsibility initiative, Sai Life Sciences has taken up the development of Kudikunta Lake in Hyderabad, reinforcing its commitment to sustainability and community well-being. The Kudikunta Lake initiative marks a significant step in restoring one of Hyderabad’s key lakes and advancing the cause of sustainable urban living. The company has […]
Read more

2025.09.05

From injections to pills: oral peptides set to transform drug development

In a recent article published in Drug Target Review, Dr Santosh Kulkarni highlights the shift from injections to pills. He writes about how oral peptide therapeutics are overcoming the long-standing challenge of poor bioavailability—bringing us closer to patient-friendly medicines without compromising efficacy. The article highlights the booming peptide drug market and the scientific advances—from chemical […]
Read more

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more